The Efficacy and Safety of Dapagliflozin in Improving Heart Failure in Dialysis Patients

Sponsor
The People's Hospital of Gaozhou
Study ID
NCT06365541
Phase
PHASE4
Status
Unknown

Conditions

  • The Efficacy and Safety of Dapagliflozin in Improving Heart Failure in Dialysis Patients

Eligibility Criteria

Sex
ALL
Age
20 Years - 70 Years
Healthy Volunteers
Not accepted

Interventions

  • Dapagliflozin — DRUG
    oral Dapagliflozin tablets 10mg/day for 6 months

Study Details

Dialysis patients have a higher incidence of cardiovascular events and require more effective measures to delay the progression of heart failure. Many studies have shown that dapagliflozin has cardioprotective effect, but most studies focus on non-dialysis patients with eGFR more than 20ml/min/1.73m2. However, the data on patients with eGFR less than 20ml/min/1.73m2 or dialysis patients, especially peritoneal dialysis patients, is less. Exploring the efficacy and safety of Dapagliflozin in improving heart failure in dialysis patients is of great clinical significance.

Key Dates

Start date
Mar 1, 2024
Status verified
Apr 2024
Primary completion
Aug 31, 2024
Completion
Aug 31, 2024

Study Design

Enrollment
40 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Self Control
    Compare the heart function of dialysis patients before treatment and during the third and sixth months of treatment.

Primary Outcome Measure

N-terminal B-type natriuretic peptide precursor (NT-proBNP) [ Time Frame: Baseline, 3 months, 6 months ]

Central Contacts